companies

Neucruit

Founded 2019
Employees 5+
Primary contact
5 Dartmouth Road
NW2 4ET London
United Kingdom
Links
https://www.neucruit.com/
Sections
Technologies
Neucruit has developed intelligent software that aims to redefine patient recruitment for clinical trials. Its technology aggregates real-time data from the over 25 million health-related conversations initiated online every day to facilitate planning and recruitment in clinical trials. Neucruit serves biopharmaceutical companies, site teams and investigators, helping them enhance site selection, optimize recruitment materials and reach groups that cannot be easily accessed through traditional methods.
Select partners: Oxford Science Park, MD Group, Imperial College London, Yale University School of Medicine, Vatic Health, Anna Freud National Centre for Children and Families, University College London, Vivan Therapeutics, University of Oxford.
Founded 2019
Employees 5+
Primary contact
5 Dartmouth Road
NW2 4ET London
United Kingdom
Links
https://www.neucruit.com/
Sections
Technologies

Funding 💰

Total $1.6M
Select investors Nina Capital, PharmStars, Right Side Capital Management, Forum Ventures, Atomico, Oxford Technology, o2h Ventures, SFC Capital

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Streamlining clinical trials: They also cost the pharmaceutical industry more than $500bn a year. Neucruit's solution cuts down on wasted time, offering a patient-centric dashboard that integrates NLP-driven outreach with onboarding, and allows users to monitor patient demographics in order to ensure diverse, transparent, and efficient trials.
  • It works: Neucruit delivered over 80% timeline reduction across over 65 clinical trials.
  • Diversity: The company's solution delivered a 670% increase in black minority ethnic participation in an anxiety and depression study.

Awards & Recognitions 🏆

  • 2021 EU Prize for Women Innovators: Rising Innovator category 🔗
  • 2021 UK Woman Who Achieves in STEM 🔗

Quotes 💬

“
We are very happy to back Neucruit, we have seen in our own portfolio the impact that slow patient recruitment can have on getting new drugs to patients.
— Sunil Shah, CEO at o2h Ventures 🔗
“
With the coronavirus pandemic likely to be with us in some form for years, solutions like Neucruit will help us adapt. Their platform will expedite research into COVID-19 and other areas of health and wellbeing.
— Jerry Allen, Director of Entrepreneurship at UCL Innovation & Enterprise 🔗
Last update: August 17, 2022